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Abstract 
Background: Accurate diagnosis of urogenital schistosomiasis is vital for surveillance and control programmes. While 
a number of diagnostic techniques are available there is a need for simple, rapid and highly sensitive point-of-need 
(PON) tests in areas where infection prevalence and intensity are low. Recombinase Polymerase Amplification (RPA) 
is a sensitive isothermal molecular diagnostic technology that is rapid, portable and has been used at the PON for 
several pathogens.
Results: A real time fluorescence RPA assay (RT-ShDra1-RPA) targeting the Schistosoma haematobium Dra1 genomic 
repeat region was developed and was able to detect 1 fg of S. haematobium gDNA. Results were obtained within 10 
minutes using a small portable battery powered tube scanner device that incubated reactions at 40 °C, whilst detect-
ing DNA amplification and fluorescence over time. The assay’s performance was evaluated using 20 urine samples, 
with varying S. haematobium egg counts, from school children from Pemba Island, Zanzibar Archipelago, Tanzania. 
Prior to RPA analysis, samples were prepared using a quick crude field DNA extraction method, the Speed Extract 
Kit (Qiagen, Manchester, UK). Positive assay results were obtained from urine samples with egg counts of 1–926 
eggs/10 ml, except for two samples, which had inconclusive results. These two samples had egg counts of two and 
three eggs/10 ml of urine.
Conclusions: The RT-ShDra1-RPA assay proved robust for S. haematobium gDNA detection and was able to amplify 
and detect S. haematobium DNA in urine samples from infected patients. The assay’s speed and portability, together 
with the use of crude sample preparation methods, could advance the rapid molecular diagnosis of urogenital schis-
tosomiasis at the PON within endemic countries.
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Background
Schistosomiasis is a neglected tropical disease (NTD) 
caused by parasitic trematodes called schistosomes. 
Schistosoma haematobium is one of three main human-
infecting schistosome species; with > 110 million cases 
of urogenital schistosomiasis, causing haematuria, blad-
der wall pathology, hydronephrosis leading to severe 
kidney disease [1, 2], and bladder cancer [3], with female 
and male genital schistosomiasis also being linked to 
infertility and HIV transmission [4]. It is the most com-
monly occurring schistosome species and is transmitted 
by various intermediate snail hosts of the genus Bulinus 
throughout Africa, parts of the Middle East, Madagascar 
and the Indian Ocean Islands [5] with a recent outbreak 
on the Mediterranean island of Corsica [6].
Sensitive and specific diagnostic tests are critical for the 
development, implementation and success of schistoso-
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not only enable the accurate diagnosis and treatment of 
individual patients but also support the monitoring of 
control interventions [11–17]. Moreover, as a control 
programme achieves success, low infection intensity is 
common within the population, with a high proportion 
of those infected excreting low numbers of schistosome 
eggs that may escape detection by routine methods, 
namely urine filtration and haematuria detection strips 
[16, 17]. This increases the need for diagnostic sensitivity 
and specificity to prevent false negative diagnoses [7, 17]. 
The recently developed, and very promising, circulating 
anodic antigen (CAA) based test offers high sensitivity 
and is currently being optimized and evaluated for PON 
testing [18, 19].
Molecular diagnostics can be highly sensitive and spe-
cific [15]. Polymerase chain reaction (PCR) and quan-
titative PCR (qPCR) methods, that target and amplify 
schistosome DNA from urine and stool samples, have 
been shown to be sensitive (0.01–10 fg) and specific [20–
23]. However, these methods are costly, take time, require 
a significant laboratory infrastructure and training, ham-
pering their current use in endemic field settings [12, 15, 
24]. Loop-mediated isothermal amplification (LAMP), 
overcomes some of these obstacles and has been success-
fully used in the field to diagnose human S. haematobium 
infections [25, 26].
Recombinase polymerase amplification (RPA) is an iso-
thermal DNA amplification technology that can be per-
formed in the field due to its low resource requirements. 
Reactions are rapid and take place at a low constant tem-
perature using small portable devices and lyophilized 
reagents. DNA amplification can be detected either by 
gel electrophoresis, oligo chromatographic lateral flow 
(LF) strips or real time fluorescence, offering detection 
flexibility of use in endemic field settings [27–30]. A 
lateral flow RPA assay targeting the Dra1 repeat region 
(Dra1 LF-RPA) has already been developed for S. haema-
tobium [31], and its specificity tested against other uri-
nary pathogens. Here, we advance this research with the 
first laboratory development and testing of a novel fluo-
rescence real time (RT) Dra1-RPA assay for S. haemato-
bium (RT-ShDra1-RPA).
Methods
Schistosoma haematobium template DNA
For the assay development S. haematobium adult worm 
genomic DNA (gDNA) originating from the Zanzibar 
island Unguja was provided by the Schistosomiasis Col-
lection at the Natural History Museum (SCAN) [32]. 
DNA was quantified using a Qubit 2.0 Fluorimeter (Invit-
rogen, California, USA) and diluted to a working concen-
tration of 1 ng/µl in  ddH20.
RPA assay development
RT‑ShDra1‑RPA primer design
The Dra1 lateral flow RPA primers and internal probe 
(Dra1 LF-RPA) designed by Rosser et al. [31] were further 
adapted for RT-ShDra1-RPA amplification and detec-
tion. The internal probe was modified for the RT fluo-
rescence-based detection as shown in Table 1 and Fig 1. 
RPA reactions were performed using the TwistAmp exo 
kit (TwistDX, UK) in 50  µl reactions containing 29.5  μl 
rehydration buffer, 2.1 μl of each of the forward and the 
reverse primers (10 pmol), 0.6  μl of the internal lateral 
flow probe (10 pmol), 12.2  μl of  ddH2o and the DNA 
template (1  ng), which were added to the lyophilized 
Table 1 Sequences of the RT-ShDra1-RPA primers (forward and reverse) and the internal probe together with a description of the 
specific probe design for the assay
Primer/probe Sequence (5′–3′)
Forward ATC TCA CCT ATC AGA CGA AAC AAA GAA AAT 
Reverse AAT ATG AAA CAA TTT TCA CAA CGA TAC GAC 
Probe AAT TGT TGG TGG AAG TGC CTG TTT CGCAA(FAM)(THF)(Q)CTC CGG AAT GGT TG(C3) (46–52 bp long, 30 bp between 5′-end and THF with 
a minimum of 15 bp between the THF and the 3′-end of the probe; THF, a basic tetrahydrofuran residue or dSpacer (replaces any 
bp between the FAM and Q; C3, spacer at the 3’-end; Q, Quencher replaces a T; FAM, replaces a T)
Fig. 1 Dra1 repeat sequence showing the position of the RT-ShDra1-RPA primers (underlined) and probe (bold)
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RPA pellet. The reactions were initiated by the addition 
of 2.5 μl (280 mM) of magnesium acetate. The reactions 
were run at 40  °C for 20 minutes in an Axxin T-16 iso-
thermal device (T-16 ISO) (http://www.axxin .com/Molec 
ular-T16), which measures the increase in fluorescence, 
due to DNA amplification, over time. The reactions were 
manually mixed after 4 minutes.
RT‑ShDra1‑RPA sensitivity testing
Sensitivity was determined by running the RPA assay, as 
described above, using dilutions (1 ng, 1 pg, 1 fg and 0.5 
fg) of the S. haematobium gDNA. Negative (no template) 
and positive (gDNA 1 ng) controls were run with the 
reactions.
Pilot urine testing
As part of the Zanzibar Elimination of Schistosomiasis 
Transmission (ZEST) project (2011–2017) [33], 1.5  ml 
aliquots of urine samples from schoolchildren that par-
ticipated in the annual surveys, were frozen at −20  °C, 
and kept at the Public Health Laboratory-Ivo de Carneri 
(PHL-IdC) on Pemba Island, Zanzibar. All urine samples 
included in the study presented here were collected in 
2013 and were positive for S. haematobium eggs, identi-
fied by urine filtration (10  ml) during the ZEST parasi-
tological surveys [33]. Twenty egg-positive urine samples 
were selected with a range of egg counts classified as very 
low, low, medium and high (Table 2). The samples were 
randomly selected from multiple Shehias, so as not to 
introduce any geographical biases, but they were strati-
fied by egg count.
At PHL-IdC, urine samples were defrosted, mixed 
and a 100 μl aliquot taken from each sample for DNA 
extraction. DNA was extracted, in country at PHL, from 
individual samples using the Qiagen Speed Extract 
kit (Qiagen). This is a fast, field-friendly and low-cost 
method for crude extraction of DNA using basic equip-
ment. The protocol followed the manufacturerʼs rec-
ommendation with slight modification. All reagents 
were supplied within the Qiagen Speed Extract kit 
(Qiagen). 200 μl of EN buffer and 15 μl of the magnet 
bead mix was added  to each urine sample, which was 
then mixed and incubated at room temperature for 
3  min before being placed on a magnetic separation 
rack (New England Biolabs, Massachusetts, USA) for 
1  min. During this time, DNA binds to the magnetic 
beads forming a pellet, allowing the supernatant to be 
removed and the pellet to be re-suspended in 100 μl of 
SL buffer to release the DNA from the beads. Samples 
were then heated at 95  °C for 5  min before returning 
to the magnetic rack for 1  min to pellet the magnetic 
beads. The supernatant, now containing extracted 
DNA, was removed and stored at room temperature. 
DNA samples were transported, at ambient tempera-
ture, to the Natural History Museum, London, UK, 
for RPA testing. Samples were analysed using the RT-
ShDra1-RPA assay as described above using 5 μl of the 
DNA preparation in the 50 μl RPA reaction. A negative 
urine control (from a NHM laboratory staff member) 
and a positive control (donor urine spiked with S. hae-
matobium gDNA) were also prepared using the Speed 
Extraction protocol and run alongside the urine sam-
ples from PHL-IdC.
Results
RT‑ShDra1‑RPA assay development and limit of detection
As shown in Fig. 2a, using 1ng of gDNA, the developed 
RT-ShDra1-RPA assay gave a positive fluorescent sig-
moid curve which appeared after ~5  min of reaction 
time. There was a lower detection limit of 1 fg of gDNA 
with the final results obtained within 10 min.
Urine sample examination
Fourteen urine samples were analysed from the medium 
and high egg count categories (Table 2), all of which gave 
a strong positive sigmoid fluorescent curve obtained 
Table 2 Egg counts (per 10 ml of urine) for the urine samples 
tested, their egg count category (high > 400; medium 51–400; 
and very low 1–10) and their RPA results
Key: +, positive; –, negative; ?, cannot interpret
Notes: There were no samples in the egg count range of 11–50. The urine code 
corresponds to the RPA curves shown in Fig. 2
Category Egg count/10 ml Urine code RPA results
High 532 U1 +
Medium 102 U2 +
Very Low 8 U3 +
Medium 156 U4 +
High 816 U5 +
High 458 U6 +
Medium 145 U7 +
Medium 368 U8 +
High 750 U9 +
Medium 137 U10 +
High 742 U11 +
High 552 U12 +
High 926 U13 +
Medium 171 U14 +
Medium 68 U15 +
Very low 3 U16 +
Very low 1 U17 +
Very low 2 U18 ?
Very low 3 U19 –
Very low 1 U20 +
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within 8 min (Fig.  2b, c). As indicated in Table  2, for 
the six urine samples in the very low egg count cat-
egory (1–10 eggs per 10  ml), the results were less easy 
to interpret. Four of the six samples produced strong 
positive sigmoid curves but one (U18, 2 eggs/10  ml) 
showed an inconclusive result (Fig. 2b, c) and one (U19, 
3 eggs/10  ml) did not show any significant rise in  fluo-
rescence and was therefore considered negative. Positive 
and negative results were obtained from the spiked (USp) 
and non-spiked (U-ve) donor urine samples, respectively 
(Fig. 2d).
Discussion
Schistosomiasis control programs aim to reduce disease 
morbidity and significant impact has been observed in 
certain areas, including the Zanzibar islands [8, 34–37]. 
However, progress in control and eventual elimination, of 
schistosomiasis, needs high performance diagnostic tests 
that can detect low levels of infection [7, 17]. The molec-
ular detection of S. haematobium DNA in urine has been 
shown to be a highly sensitive indicator of infection [15, 
22, 23]. RPA is a DNA amplification and detection tech-
nology that is particularly suitable for PON use [24, 31–
37], as all reagents are readily available lyophilized with 
the main RPA reagents provided in a single dried pellet, 
simplifying assay preparation, reducing contamination 
and allowing easy transportation and long-term storage 
at room temperature. Additionally, DNA amplification 
occurs at low constant temperatures between 25–40  °C 
and real time fluorescence amplification detection can 
be performed using small portable tube-scanner devices, 
with results obtained within 20 minutes.
Fig. 2 RPA fluorescent curves for the S. haematobium gDNA dilutions and the urine samples tested from PHL-IDC, Pemba. a S. haematobium gDNA 
dilutions. b Urine samples U3-15. c Urine samples U1+2 (high egg counts) and U16-20 (very low egg counts). d Urine samples U1+2 (high egg 
counts) and negative donor urine (U-ve) and negative donor urine spiked with S. haematobium gDNA (USp). sDNA corresponds to a DNA standard 
positive control. −ve corresponds to negative controls
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Here, a real time fluorescence-based RPA assay was 
successfully developed to amplify the Dra1 DNA repeat 
region of S. haematobium (RT-ShDra1-RPA). The pre-
sent RT-ShDra1-RPA lower limit of detection was 1 fg 
of S. haematobium gDNA, lower than the existing Dra1 
end point PCR diagnostic assay, that has a detection limit 
of 10 fg of S. haematobium gDNA [38], and also lower 
than the detection limit of the developed lateral flow 
RPA Dra1 assay (LF-ShDra1-RPA) [31], that had a detec-
tion limit of 100 fg of gDNA. However, the Dra1 qPCR 
and LAMP assays have been reported to display higher 
sensitivities detecting as low as 1 fg and 0.1 fg of S. hae-
matobium gDNA, respectively [15, 20–23, 25, 26]. Theo-
retically, RPA can detect a single copy of a DNA target 
thus there is scope for further assay optimization and 
development, particularly focusing upon different target 
regions, probe and primer combinations and concentra-
tions to increase assay sensitivity.
RPA has been shown to offer degrees of tolerance to 
inhibitors found in urine, and works well on crudely pre-
pared samples [30] reducing the need for the resources 
needed for sophisticated sample preparation and purifi-
cation methods, further enhancing its feasibility for PON 
use. The RT-ShDra1-RPA developed here gave positive 
results when tested on crudely prepared urine samples 
from infected school children from the endemic Pemba 
Island, Zanzibar. The DNA preparations took ~15  min-
utes for 12 samples and required only portable low pow-
ered equipment. The assay produced strong positive 
results for samples that had medium to high egg counts 
(11–926 eggs per 10  ml), performing as well as micros-
copy but further analysis of samples with lower egg 
counts is warranted, particularly as this is the main appli-
cation for this type of diagnostic. Results varied between 
samples that had between 1–10 eggs per 10  ml. Four 
among the 6 samples, within this egg count range, gave 
positive results but one was inconclusive and one was 
negative. This maybe due to there not being eggs present 
in the aliquot of urine analysed, false positive egg identi-
fication by microscopy and/or sample degradation. It is 
worth mentioning that two of the three urine filtration 
reads (each sample was read by three technicians) per-
formed on these samples were recorded as egg-negative. 
Further testing of low egg count samples and egg-neg-
ative samples is now needed to further  assess the per-
formance of the developed assay. It is also necessary to 
determine if this method is detecting DNA from the S. 
haematobium eggs or Cell-Free-Parasite DNA (CFPD), 
which has been reported as a source of DNA in PCR 
and qPCR assays [15, 39]. RPA reactions are only semi-
quantitative with the time to onset of amplification being 
longer for low and quicker for high DNA concentrations 
(Fig. 2a) and hence, could currently be used preferentially 
to identify infected individuals, but not to evaluate infec-
tion intensities.
The extraction method used for this study was cho-
sen due to its field applicability and in particular its low 
resource needs, speed and simplicity. The SpeedXtract 
method works well for RPA assays as high quality DNA 
and purity is not needed. However, comparisons with 
other standard extraction methods would be beneficial 
as this may increase sensitivity. Particularly, as laborato-
ries in endemic countries grow their infrastructure, more 
high resource sample preparation methods may become 
feasible.
Although the ShDra1-RPA assayʼs primer and probe 
combinations have proved negative with regard to their 
cross-reactivity with other pathogens found in urine 
samples and also other schistosome species, this has only 
been fully tested in the lateral flow form [31]. Here the 
developed RT-ShDra1-RPA assay is predicted to show 
the same specificity as the primer and probes used are 
identical except that  they are modified for fluorescent 
detection. However, full validation on reference pathogen 
samples and also testing on a range of well-defined nega-
tive clinical  samples is warranted to further validate the 
RT-ShDra1-RPA assayʼs clinical specificity.
Defining the gold standard for the diagnosis of schis-
tosomiasis is not easy and there is no real current con-
sensus. Currently egg detection in clinical samples is 
commonly used but this is known to not have the clini-
cal sensitivity needed in low prevalence and intensity set-
tings. Diagnosis by qPCR [20–23] is also used as a gold 
standard in some laboratories with CAA testing also 
coming on to the agenda however, comparisons between 
all tests are warranted. In this study the RT-ShDra1-RPA 
assay has been tested with regard to egg count in a small 
set of samples but the assay certainly needs testing on a 
wider range, and on a  number of well-defined samples 
together with direct comparisons to qPCR and CAA [18, 
19]. These comparisons are needed to define the diagnos-
tic use case, for such an assay as RPA, in relation to its 
possible utility at different stages of schistosomiasis con-
trol [10–13]. Certainly, the characteristics of RPA could 
support diagnosis and possible test and treat scenarios at 
the elimination stage.
Conclusions
The developed RT-ShDra1-RPA assay offers an alterna-
tive S. haematobium DNA amplification system that has 
the potential use as a molecular diagnostic tool for uro-
genital schistosomiasis in endemic settings. Results can 
be rapidly obtained from crudely prepared samples using 
small portable devices requiring minimal infrastructure. 
Further development is needed to test its sensitivity and 
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performance in low prevalence settings, where infection 
intensities and egg counts are mostly low, and in compar-
ison to existing diagnostic tests.
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